{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:56:07Z","timestamp":1776459367592,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"DOI":"10.7759\/cureus.107249","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:06:37Z","timestamp":1776456397000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimising Radiotherapy for Prostate Cancer: Comparison of Treatment Schedules and Toxicities"],"prefix":"10.7759","author":[{"given":"Kanumuri","family":"Asha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"JS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathya","family":"Narayanan MS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemavathi","family":"TM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley D","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al.. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016, 17:p1047-60.","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky MJ","year":"2002","unstructured":"Zelefsky MJ, Fuks Z, Hunt M, et al.. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002, 53:1111-6. 10.1016\/s0360-3016(02)02857-2","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/02841860410002824","article-title":"The radiobiology of prostate cancer including new aspects of fractionated radiotherapy","volume":"44","author":"Fowler JF","year":"2005","unstructured":"Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005, 44:265-76. 10.1080\/02841860410002824","journal-title":"Acta Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG Oncology RTOG 0415: a randomized Phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee WR","year":"2024","unstructured":"Lee WR, Dignam JJ, Amin MB, et al.. Long-term analysis of NRG Oncology RTOG 0415: a randomized Phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2024, 42:2377-81. 10.1200\/JCO.23.02445","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton CN","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, et al.. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017, 35:1884-90. 10.1200\/JCO.2016.71.7397","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci L","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG, et al.. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016, 17:P1061-9. 10.1016\/S1470-2045(16)30070-5","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2022.0116","article-title":"Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer","volume":"27","author":"Soni A","year":"2022","unstructured":"Soni A, Jadhav GK, Manocha S, Chauhan S, Goswami B, Verma M. Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer. Rep Pract Oncol Radiother. 2022, 27:1001-9. 10.5603\/RPOR.a2022.0116","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.01.004","article-title":"Moderately hypofractionated radiotherapy in node-positive prostate cancer","volume":"31","author":"Mallick I","year":"2019","unstructured":"Mallick I, Das A, Arunsingh M. Moderately hypofractionated radiotherapy in node-positive prostate cancer. Clin Oncol (R Coll Radiol). 2019, 31:260-4. 10.1016\/j.clon.2019.01.004","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler JL","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, et al.. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019, 17:479-505. 10.6004\/jnccn.2019.0023","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.1268","article-title":"Ultra-short-course hormone therapy for intermediate risk prostate cancer treated with definitive radiotherapy: retrospective analysis of a national healthcare system","volume":"120","author":"Pflederer T","year":"2024","unstructured":"Pflederer T, Miller SR, Jackson WC, et al.. Ultra-short-course hormone therapy for intermediate risk prostate cancer treated with definitive radiotherapy: retrospective analysis of a national healthcare system. Int J Radiat Oncol Biol Phys. 2024, 120:E574.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker CC","year":"2024","unstructured":"Parker CC, Kynaston H, Cook AD, et al.. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024, 403:2416-25. 10.1016\/S0140-6736(24)00549-X","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier C","year":"2018","unstructured":"Salembier C, Villeirs G, De Bari B, et al.. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol. 2018, 127:49-61. 10.1016\/j.radonc.2018.01.014","journal-title":"Radiother Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry MJ","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992, 148:1549-57; discussion 1564. 10.1016\/s0022-5347(17)36966-5","journal-title":"J Urol"},{"key":"ref15","article-title":"PSA nadir predicts biochemical recurrence after external beam radiation therapy combined to high dose rate brachytherapy in the treatment of prostate cancer","volume":"10","author":"Coelho MO","year":"2022","unstructured":"Coelho MO, Dal Col LS, Capibaribe DM, et al.. PSA nadir predicts biochemical recurrence after external beam radiation therapy combined to high dose rate brachytherapy in the treatment of prostate cancer. Am J Clin Exp Urol. 2022, 10:52-62.","journal-title":"Am J Clin Exp Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox JD","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995, 31:1341-6. 10.1016\/0360-3016(95)00060-C","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-3","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes","volume":"6","author":"Freeman DE","year":"2011","unstructured":"Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011, 6:3. 10.1186\/1748-717X-6-3","journal-title":"Radiat Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark A","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al.. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019, 394:385-95. 10.1016\/S0140-6736(19)31131-6","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4102\/sajo.v9i0.327","article-title":"Acute toxicities of moderately hypofractionated radiotherapy in the treatment of localised prostate cancer","volume":"9","author":"Roos E","year":"2025","unstructured":"Roos E, Pillay K, Bassa S. Acute toxicities of moderately hypofractionated radiotherapy in the treatment of localised prostate cancer. S Afr J Oncol. 2025, 9:a327. 10.4102\/sajo.v9i0.327","journal-title":"S Afr J Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.meddos.2017.07.002","article-title":"Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials","volume":"42","author":"Jones RT","year":"2017","unstructured":"Jones RT, Hassan Rezaeian N, Desai NB, et al.. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. Med Dosim. 2017, 42:341-7. 10.1016\/j.meddos.2017.07.002","journal-title":"Med Dosim"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2022-0018","article-title":"Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements","volume":"56","author":"Moll M","year":"2022","unstructured":"Moll M, Herrmann H, Zaharie A, Goldner G. Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements. Radiol Oncol. 2022, 56:365-70. 10.2478\/raon-2022-0018","journal-title":"Radiol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/463435-optimising-radiotherapy-for-prostate-cancer-comparison-of-treatment-schedules-and-toxicities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:06:38Z","timestamp":1776456398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/463435-optimising-radiotherapy-for-prostate-cancer-comparison-of-treatment-schedules-and-toxicities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.107249","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}